Tag: Statins
Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C
Greater reduction seen in LDL-C; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence
Statins May Reduce Risk for Hepatocellular Carcinoma in Chronic Liver Disease
Improved Fibrosis-4 group transitions seen over time for patients with chronic liver disease using statins
Small but Important Differences Seen Between Rosuvastatin, Atorvastatin
Rosuvastatin tied to cardiovascular and mortality benefits but also higher risk for type 2 diabetes
Metabolic Risk Contributes to Diabetes Onset in People With HIV
Metabolic risk factors contribute to new-onset diabetes mellitus among those treated with pitavastatin or placebo
Statin Therapy Cost-Effectively Improves Health Outcomes for ≥70s
Lifetime use of standard statin increased QALYs by 0.24 to 0.70, with further increase seen for higher-intensity statins
PREVENT Equations Reclassify Half of U.S. Adults to Lower ASCVD Risk
Considerable decrease estimated in U.S. adults receiving or recommended for preventive treatment with statins, antihypertensives
Fewer Adults Eligible for Statins With PREVENT Equations
Most adults eligible for statins based on PREVENT equations did not report statin use
Statin Initiation Cuts Mortality in Older Adults With Chronic Kidney Disease
Findings seen among older adults with stage 3 to 4 disease with no prior atherosclerotic cardiovascular disease
Lipid-Lowering Drugs Save Lives, but Use Decreasing
In 2019 to 2020, 56 percent of patients with high cholesterol were on statins for primary prevention and 85 percent for secondary prevention
Rosuvastatin, Atorvastatin Have Comparable Efficacy for CAD
Comparable efficacy seen for composite outcome; rosuvastatin linked to lower LDL-cholesterol levels
